{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:06:43Z","timestamp":1793394403050,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01325-6","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:37:51Z","timestamp":1760445471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oligometastatic Gastric Cancer: Novel Considerations for Personalized Approach"],"prefix":"10.1007","volume":"56","author":[{"given":"Gerasimia D.","family":"Kyrochristou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios D.","family":"Lianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra D.","family":"Kyrochristou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Mitsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Vlachos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"4","key":"1325_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s10120-024-01520-7","volume":"27","author":"P Morgagni","year":"2024","unstructured":"Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al. Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape. Gastric Cancer. 2024;27(4):672\u20134.","journal-title":"Gastric Cancer"},{"key":"1325_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119131","author":"N Felipez","year":"2023","unstructured":"Felipez N, Montori S, Mendizuri N, Llach J, Delgado PG, Moreira L, et al. The human gastric juice: a promising source for gastric cancer biomarkers. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24119131.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1325_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"8","key":"1325_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2217\/fon.13.78","volume":"9","author":"CD Bali","year":"2013","unstructured":"Bali CD, Lianos GD, Roukos DH. Gastric cancer guidelines and genome differences between Japan and the west. Future Oncol. 2013;9(8):1053\u20136.","journal-title":"Future Oncol"},{"issue":"1","key":"1325_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer A","year":"2023","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"issue":"3","key":"1325_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/fon.14.283","volume":"11","author":"S Rausei","year":"2015","unstructured":"Rausei S, Ruspi L, Mangano A, Lianos GD, Galli F, Boni L, et al. Advantages of staging laparoscopy in gastric cancer: they are so obvious that they are not evident. Future Oncol. 2015;11(3):369\u201372.","journal-title":"Future Oncol"},{"issue":"2","key":"1325_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4251\/wjgo.v14.i2.434","volume":"14","author":"M Chevallay","year":"2022","unstructured":"Chevallay M, Wassmer CH, Iranmanesh P, Jung MK, Monig SP. \u2018Multimodal treatment in oligometastatic gastric cancer.\u2019 World J Gastrointest Oncol. 2022;14(2):434\u201349.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"1325_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318.","journal-title":"Lancet Oncol"},{"key":"1325_CR9","doi-asserted-by":"publisher","DOI":"10.1590\/0102-672020230034e1752","volume":"36","author":"PP Assumpcao","year":"2023","unstructured":"Assumpcao PP, Silva J, Calcagno DQ, Barra WF, Ishak G, Kassab P. Oligometastasis in gastric cancer treatment: is there a place for the surgeon? ABCD Arquivos Brasileiros de Cirurgia Digestiva (S\u00e3o Paulo). 2023;36:e1752.","journal-title":"ABCD Arquivos Brasileiros de Cirurgia Digestiva (S\u00e3o Paulo)"},{"issue":"5","key":"1325_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clinre.2020.02.003","volume":"44","author":"P Jin","year":"2020","unstructured":"Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin Res Hepatol Gastroenterol. 2020;44(5):638\u201345.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7\u20138","key":"1325_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000531590","volume":"46","author":"M Hingorani","year":"2023","unstructured":"Hingorani M, Stubley H. Management of oligometastatic disease in esophagogastric cancer: what is the evidence? Oncol Res Treat. 2023;46(7\u20138):312\u20139.","journal-title":"Oncol Res Treat"},{"issue":"8","key":"1325_CR12","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1245\/s10434-022-11541-0","volume":"29","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, Buijs GS, Burger MDL, Ruurda JP, Mook S, Brosens LAA, et al. Metastasectomy or stereotactic body radiation therapy with or without systemic therapy for oligometastatic esophagogastric cancer. Ann Surg Oncol. 2022;29(8):4848\u201357.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1325_CR13","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1325_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejso.2022.09.012","volume":"49","author":"TE Kroese","year":"2023","unstructured":"Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, et al. Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol. 2023;49(1):21\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"1325_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","volume":"166","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer. 2022;166:254\u201369.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1325_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1515\/pp-2022-0111","volume":"7","author":"F Casella","year":"2022","unstructured":"Casella F, Bencivenga M, Rosati R, Fumagalli UR, Marrelli D, Pacelli F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne. Pleura and Peritoneum. 2022;7(3):135\u201341.","journal-title":"Pleura and Peritoneum"},{"key":"1325_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.radonc.2022.06.012","volume":"173","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, Christ SM, van Rossum PSN, Burger MDL, Buijs GS, Muhlematter U, et al. \u2018Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.\u2019 Radiother Oncol. 2022;173:269\u201376.","journal-title":"Radiother Oncol"},{"key":"1325_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2021.11.032","volume":"164","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne P, Nafteux P, Obermannova R, et al. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer. 2022;164:18\u201329.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1325_CR19","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. \u2018Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237\u201344.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1325_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1325_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. \u2018The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO\/CAO-V\/CAOGI.\u2019 BMC Cancer. 2017;17(1):893.","journal-title":"BMC Cancer"},{"issue":"8","key":"1325_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jclinepi.2014.03.004","volume":"67","author":"AB Smith","year":"2014","unstructured":"Smith AB, Cocks K, Taylor M, Parry D. Most domains of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 are reliable. J Clin Epidemiol. 2014;67(8):952\u20137.","journal-title":"J Clin Epidemiol"},{"key":"1325_CR23","doi-asserted-by":"crossref","unstructured":"Mielko J, Rawicz-Pruszynski K, Skorzewska M, Cisel B, Pikula A, Kwietniewska M, Geca K., Sedlak K, Kurylcio A, Polkowski WP. \u2018Conversion surgery with HIPEC for peritoneal oligometastatic gastric cancer\u2019. Cancers (Basel), 2019;11(11).","DOI":"10.3390\/cancers11111715"},{"issue":"1","key":"1325_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2478\/raon-2020-0067","volume":"55","author":"T Jagric","year":"2020","unstructured":"Jagric T, Horvat M. Surgical resection of synchronous liver metastases in gastric cancer patients. A propensity score-matched study. Radiol Oncol. 2020;55(1):57\u201365.","journal-title":"Radiol Oncol"},{"issue":"2","key":"1325_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. \u2018International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6(2):227\u201340.","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"1325_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-020-01035-9","volume":"21","author":"M Runkel","year":"2021","unstructured":"Runkel M, Verst R, Spiegelberg J, Fichtner-Feigl S, Hoeppner J, Glatz T. \u2018Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.\u2019 BMC Surg. 2021;21(1):35.","journal-title":"BMC Surg"},{"key":"1325_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58121802","author":"CE Minciuna","year":"2022","unstructured":"Minciuna CE, Tudor S, Micu A, Diaconescu A, Alexandrescu ST, Vasilescu C. \u2018Safety and efficacy of simultaneous resection of gastric carcinoma and synchronous liver metastasis-a western center experience.\u2019 Medicina (Kaunas). 2022. https:\/\/doi.org\/10.3390\/medicina58121802.","journal-title":"Medicina (Kaunas)"},{"key":"1325_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040797","author":"SJM van Hootegem","year":"2024","unstructured":"van Hootegem SJM, de Pasqual CA, Giacopuzzi S, Van Daele E, Vanommeslaeghe H, Moons J, et al. Outcomes after surgical treatment of oesophagogastric cancer with synchronous liver metastases: a multicentre retrospective cohort study. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16040797.","journal-title":"Cancers (Basel)"},{"key":"1325_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010170","author":"M Bencivenga","year":"2023","unstructured":"Bencivenga M, Ministrini S, Morgagni P, Mura G, Marrelli D, Milandri C, et al. Oligometastatic gastric cancer: clinical data from the meta-gastro prospective register of the Italian Research Group on Gastric Cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers16010170.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1325_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275\u201384.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1325_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12528","volume":"21","author":"R Giampieri","year":"2021","unstructured":"Giampieri R, Cantini L, Del Prete M, Bittoni A, Giglio E, Mandolesi A, et al. \u2018An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer.\u2019 Oncol Lett. 2021;21(4):267.","journal-title":"Oncol Lett"},{"key":"1325_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071376","author":"D Marrelli","year":"2024","unstructured":"Marrelli D, Piccioni SA, Carbone L, Petrioli R, Costantini M, Malagnino V, et al. Posterior and para-aortic (D2plus) lymphadenectomy after neoadjuvant\/conversion therapy for locally advanced\/oligometastatic gastric cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16071376.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1325_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"1325_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF02306611","volume":"4","author":"T Nakajima","year":"1997","unstructured":"Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, et al. \u2018Combined intensive chemotherapy and radical surgery for incurable gastric cancer.\u2019 Ann Surg Oncol. 1997;4(3):203\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1325_CR35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3892\/ol_00000130","volume":"1","author":"T Suzuki","year":"2010","unstructured":"Suzuki T, Tanabe K, Taomoto J, Yamamoto H, Tokumoto N, Yoshida K, et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 2010;1(4):743\u20137.","journal-title":"Oncol Lett"},{"key":"1325_CR36","doi-asserted-by":"crossref","unstructured":"Ministrini S, Bencivenga M, Solaini L, Cipollari C, Sofia S, Marino E, d'Ignazio A, Molteni B, Mura G, Marrelli D, Degiuli M, Donini A, Roviello F, de Manzoni G, Morgagni P, Tiberio GAM. \u2018Stage IV gastric cancer: the surgical perspective of the Italian Research Group on Gastric Cancer\u2019. Cancers (Basel) 2020;12(1).","DOI":"10.3390\/cancers12010158"},{"issue":"2","key":"1325_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11864-022-01042-3","volume":"24","author":"K Beyer","year":"2023","unstructured":"Beyer K. Surgery matters: progress in surgical management of gastric cancer. Curr Treat Options Oncol. 2023;24(2):108\u201329.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"1325_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000455683","volume":"33","author":"C Chiapponi","year":"2017","unstructured":"Chiapponi C, Berlth F, Plum PS, Betzler C, Stippel DL, Popp F, et al. Oligometastatic disease in upper gastrointestinal cancer - how to proceed? Visc Med. 2017;33(1):31\u20134.","journal-title":"Visc Med"},{"key":"1325_CR39","doi-asserted-by":"crossref","unstructured":"Kroese TETY, Lordick F, van Rossum PSN, Ruurda JP, Lagarde SM, van Hillegersberg R, Verhoeven RHA, van Laarhoven HWM. \u2018Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study\u2019. Eur J Cancer 2023","DOI":"10.2139\/ssrn.4167742"},{"key":"1325_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrv.2018.05.010","volume":"69","author":"F Montagnani","year":"2018","unstructured":"Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, et al. \u2018Long-term survival after liver metastasectomy in gastric cancer: systematic review and meta-analysis of prognostic factors.\u2019 Cancer Treat Rev. 2018;69:11\u201320.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1325_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.currproblcancer.2017.03.003","volume":"41","author":"B Polkowska-Pruszynska","year":"2017","unstructured":"Polkowska-Pruszynska B, Rawicz-Pruszynski K, Cisel B, Sitarz R, Polkowska G, Krupski W, et al. Liver metastases from gastric carcinoma: a case report and review of the literature. Curr Probl Cancer. 2017;41(3):222\u201330.","journal-title":"Curr Probl Cancer"},{"issue":"3","key":"1325_CR42","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.18632\/oncotarget.14027","volume":"8","author":"J Chen","year":"2017","unstructured":"Chen J, Kong Y, Weng S, Dong C, Zhu L, Yang Z, et al. Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database. Oncotarget. 2017;8(3):4342\u201351.","journal-title":"Oncotarget"},{"issue":"8","key":"1325_CR43","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/jso.23920","volume":"111","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Lonati V, et al. Hepatic resection for gastric cancer liver metastases: a systematic review and meta-analysis. J Surg Oncol. 2015;111(8):1021\u20137.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1325_CR44","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/SLA.0000000000001542","volume":"263","author":"SR Markar","year":"2016","unstructured":"Markar SR, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M, et al. \u2018Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis.\u2019 Ann Surg. 2016;263(6):1092\u2013101.","journal-title":"Ann Surg"},{"issue":"6","key":"1325_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5306\/wjco.v6.i6.291","volume":"6","author":"S Ito","year":"2015","unstructured":"Ito S, Ito Y, Misawa K, Shimizu Y, Kinoshita T. Neoadjuvant chemotherapy followed by surgery in gastric cancer patients with extensive lymph node metastasis. World J Clin Oncol. 2015;6(6):291\u20134.","journal-title":"World J Clin Oncol"},{"key":"1325_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijscr.2020.08.033","volume":"75","author":"FR Takeda","year":"2020","unstructured":"Takeda FR, Garcia RN, Ueda SKN, Peixoto RD, Sallum RAA, Cecconello I. Primary tumor resection of metastatic gastric cancer in a multimodal era: two case reports. Int J Surg Case Rep. 2020;75:42\u20135.","journal-title":"Int J Surg Case Rep"},{"issue":"6","key":"1325_CR47","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jjco\/hym067","volume":"37","author":"E Nomura","year":"2007","unstructured":"Nomura E, Sasako M, Yamamoto S, Sano T, Tsujinaka T, Kinoshita T, et al. Risk factors for para-aortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501. Jpn J Clin Oncol. 2007;37(6):429\u201333.","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"1325_CR48","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1245\/s10434-017-5857-8","volume":"24","author":"D Marrelli","year":"2017","unstructured":"Marrelli D, Ferrara F, Giacopuzzi S, Morgagni P, Di Leo A, De Franco L, et al. Incidence and prognostic value of metastases to \u201cposterior\u201d and para-aortic lymph nodes in resectable gastric cancer. Ann Surg Oncol. 2017;24(8):2273\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1325_CR49","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1245\/s10434-010-0969-4","volume":"17","author":"M Tokunaga","year":"2010","unstructured":"Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Aikou S, Yamaguchi T. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol. 2010;17(8):2031\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1325_CR50","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ejso.2016.01.002","volume":"42","author":"S Morita","year":"2016","unstructured":"Morita S, Fukagawa T, Fujiwara H, Katai H. The clinical significance of para-aortic nodal dissection for advanced gastric cancer. Eur J Surg Oncol. 2016;42(9):1448\u201354.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"1325_CR51","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3748\/wjg.14.936","volume":"14","author":"DF Shen","year":"2008","unstructured":"Shen DF, Chen DW, Quan ZW, Dong P, Wang XF, Xu HZ, et al. Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma. World J Gastroenterol. 2008;14(6):936\u20138.","journal-title":"World J Gastroenterol"},{"key":"1325_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030673","author":"I Yasufuku","year":"2024","unstructured":"Yasufuku I, Tsuchiya H, Fujibayashi S, Okumura N, Sengoku Y, Fukada M, et al. \u2018Oligometastasis of gastric cancer: a review.\u2019 Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16030673.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1325_CR53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00268-010-0396-5","volume":"34","author":"M Hioki","year":"2010","unstructured":"Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg. 2010;34(3):555\u201362.","journal-title":"World J Surg"},{"issue":"26","key":"1325_CR54","doi-asserted-by":"publisher","first-page":"43481","DOI":"10.18632\/oncotarget.16480","volume":"8","author":"JRW McMullen","year":"2017","unstructured":"McMullen JRW, Selleck M, Wall NR, Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017;8(26):43481\u201390.","journal-title":"Oncotarget"},{"key":"1325_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience-a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1\u201314.","journal-title":"Eur J Cancer"},{"key":"1325_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030570","author":"BJ Sun","year":"2022","unstructured":"Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030570.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1325_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.21037\/jgo.2019.11.05","volume":"11","author":"SP Martin","year":"2020","unstructured":"Martin SP, Drake JA, Hernandez JM, Davis JL. Bidirectional chemotherapy in patients with gastric cancer and peritoneal metastasis. J Gastrointest Oncol. 2020;11(1):108\u201311.","journal-title":"J Gastrointest Oncol"},{"key":"1325_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-121","volume":"10","author":"SP Kerkar","year":"2009","unstructured":"Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, et al. \u2018The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.\u2019 Trials. 2009;10:121.","journal-title":"Trials"},{"issue":"6","key":"1325_CR59","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1325_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, et al. \u2018Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial.\u2019 J Clin Oncol. 2024;42(2):146\u201356.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1325_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/pp-2016-0017","volume":"1","author":"V Khomyakov","year":"2016","unstructured":"Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1(3):159\u201366.","journal-title":"Pleura Peritoneum"},{"key":"1325_CR62","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne P, van Cutsem E, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024;204:114062.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1325_CR63","doi-asserted-by":"publisher","first-page":"775","DOI":"10.26574\/maedica.2024.19.4.775","volume":"19","author":"GD Lianos","year":"2024","unstructured":"Lianos GD, Kyrochristou GD, Lianou AD, Tatsis V, Schizas D, Vlachos K, et al. Gastric juice biomarkers in gastric cancer: new trends? Maedica. 2024;19(4):775\u20139.","journal-title":"Maedica"},{"issue":"10294","key":"1325_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. \u2018First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.\u2019 Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"10","key":"1325_CR65","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. \u2018Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.\u2019 JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"key":"1325_CR66","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17729-4","author":"H Liang","year":"2025","unstructured":"Liang H, Liang C, Zhang J, Sun X, Huang K, Zhang H, et al. Conversion surgery after trastuzumab-based chemotherapy and immunotherapy for stage IV HER2-positive gastric cancer: a retrospective multicenter cohort study. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17729-4.","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"1325_CR67","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.3748\/wjg.v26.i36.5408","volume":"26","author":"PH Niu","year":"2020","unstructured":"Niu PH, Zhao LL, Wu HL, Zhao DB, Chen YT. Artificial intelligence in gastric cancer: application and future perspectives. World J Gastroenterol. 2020;26(36):5408\u201319.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1325_CR68","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ejso.2018.11.006","volume":"45","author":"M Salati","year":"2019","unstructured":"Salati M, Valeri N, Spallanzani A, Braconi C, Cascinu S. Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications. Eur J Surg Oncol. 2019;45(8):1479\u201382.","journal-title":"Eur J Surg Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01325-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01325-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01325-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:02:30Z","timestamp":1760486550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01325-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01325-6","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"28 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"201"}}